TRIMTECH and Tagomics expand into new BioMed Realty lab at Babraham
The fully occupied building represents another milestone in the joint venture between BioMed Realty and Babraham Research Campus Ltd (BRC Ltd), which develops and manages the Campus on behalf of its shareholders, BBSRC–UKRI and the Babraham Institute.
TRIMTECH Therapeutics, a biotech company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, has leased fully fitted laboratory and office space, enabling the company to expand its team and combine research and management activities to one site.
The space will support TRIMTECH’s work to open up much needed small molecule approaches for indications that affect very large populations, such as Alzheimer’s disease and Huntington’s.
Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, has also signed a lease to support the continued development of its innovative multiomic platform. The platform underpins Tagomics’ work in early disease detection and precision diagnostics, including programmes supported by Innovate UK’s Biomedical Catalyst funding to advance novel diagnostic approaches for colorectal cancer in collaboration with NHS partners.
Orestis Tzortzoglou, Vice President and Head of the UK Market at BioMed Realty, said: “Completing the lease-up of this building reflects both the high quality and performance capabilities of the asset in this established campus and the success of our long-standing joint venture with Babraham Research Campus Ltd.
“Our shared focus is on delivering turnkey, mission-critical laboratory environments that allow innovative companies to move quickly from discovery to data, while remaining embedded in a collaborative research community.”
Designed to support companies transitioning from incubation through early scale-up, the building offers flexible, multi-tenant laboratory and office suites backed by robust building systems and dedicated on-site operational support. This approach reduces barriers to entry for emerging life science companies while providing a clear pathway for growth within the Campus.
Babraham Research Campus is internationally recognised for its unique co-location of commercial bioscience companies alongside the world-leading discovery research of the Babraham Institute. The Campus is home to a vibrant community of start-ups, scale-ups, and established organisations employing more than 2,000 people, alongside approximately 300 academic researchers.
Dr. Louise Jopling, Chief Scientific and Innovation Officer of Babraham Research Campus, said: “Our dynamic and highly connected Campus ecosystem is designed to support bioscience ventures at every stage of their journey.
“The full occupancy of this building demonstrates how the right combination of flexible facilities, collaborative culture, and long-term partnerships – such as our joint venture with BioMed Realty – creates an environment where innovative companies can start, scale, and stay. We welcome TRIMTECH Therapeutics and Tagomics to Babraham Research Campus, and are delighted that they have chosen us as their home.”
BioMed Realty owns and operates 17 million square feet of purpose-built laboratory and office space across the world’s top innovation hubs, including Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder, and Cambridge, UK. It has an additional 1.5 million square feet of Class A properties under development.
